Research Article

Rectus Sheath Hematoma in COVID-19 Patients as a Mortal Complication: A Retrospective Report

Hossein Zabihi Mahmoudabadi,1 Azar Hadadi,2,3 Mohammad Reza Fattahi,1,3 Samira Kafan,4 Mohammad Ashouri,5 Rashad Allahbeigi,1 and Reza Hajebi1

1Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
2Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
3Virology Research Center, Tehran University of Medical Sciences, Tehran, Iran
4Department of Pulmonary Disease, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
5Department of Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Mohammad Reza Fattahi; mrfatahi93@gmail.com

Received 30 September 2021; Revised 21 December 2021; Accepted 28 January 2022; Published 12 February 2022

1. Introduction

Rectus sheath hematoma (RSH) is a rare cause of abdominal pain in hospitalized patients. This condition commonly occurs after either a rupture of abdominopelvic arteries and their branches, especially during anticoagulation therapy or the tear of the rectus abdominis muscle [1]. Studies have warned against the development of RSH following anticoagulant treatment. It accounts for about 1.5–2% of the cases of unexplained abdominal pain in hospitalized patients [2]. The most common provoking factors are coughing, straining, exercising, hypertension, obesity, previous abdominal surgery, subcutaneous injection, prophylactic or therapeutic anticoagulation, and trauma. Trauma can be internal or external, including a strain of physical exertion, seizures, or even vomiting [3].

Clinical presentations of RSH include nausea, vomiting, fever, abdominal pain [4], and abdominal tenderness along with ecchymosis (Cullen’s or Turner’s sign) on physical examination [5].
Although a visible hematoma is a helpful sign in 50% of RSH cases [5], it can be easily screened by abdominal ultrasound (US) [2]; however, its diagnostic sensitivity for RSH is about 80–85%, and the results should be confirmed by abdominal and pelvic computed tomography (CT), which is 100% sensitive most of the time [6, 7].

There are concerns over RSH in hospitalized patients with COVID-19 [8–13]. On the one hand, these patients receive anticoagulants for thromboprophylaxis; on the other hand, any bleeding prompts clinicians to discontinue anticoagulants and control vital signs [14]. Therefore, surgeons can play an important role if bleeding progresses and vital signs are not controlled. Some predictors such as the rate of hemoglobin reduction, need for transfusion of packed red blood cells, bleeding confirmed by computed tomographic angiography, and hematoma size have been used to assess the need for angiography and embolization in recent years [15]. However, this complication and its clinical prognosis in COVID-19 patients are still unclear. This clinical retrospective multicentre study was conducted to shed light on ambiguities in this regard.

2. Material and Method

Hospital records were reviewed from June to August 2021 to extract demographic characteristics (age, gender, and BMI), past medical history, symptoms, laboratory tests, and imaging modalities supporting the diagnosis as well as treatment, duration of hospitalization, and RSH outcome.

A diagnosis of COVID-19 was made according to the chest computed tomography (CT) scan and/or real-time PCR upon admission. The severity of pulmonary involvement was assessed by a professional radiologist upon admission. RSH was diagnosed with sonography and confirmed by abdominopelvic CT in most cases after surgical consultation during the hospital stay.

Blood samples for coagulation state, inflammatory markers, and other routine tests were collected on hospital admission and repeated every day. During hospitalization, the dosing and method of anticoagulant administration were adjusted by clinicians at least twice a day based on inflammatory markers such as LDH, coagulation markers such as D-dimer, and vital signs (Table 1).

We present major RSH in nine confirmed COVID-19 patients on prophylactic or therapeutic anticoagulation treatment. The median and interquartile range were used to report the distribution of the results. Furthermore, written informed consent was obtained from the patients or their companions. This research was confirmed by the Research Ethics Committee of the Tehran University of Medical Sciences (approval id. IR.TUMS.VCR.REC.1399.462).

3. Results

About 24104 suspicious COVID-19 patients presented to respiratory triages, of whom 3820 were admitted. Nine cases were complicated with RSH.

The median age was 65 (22.5) years, most of them were females (F/M ratio: 8), the median length of hospital stay was 20 (13.5) days, and the length of anticoagulant treatment was 20 (13.5) days overall. The median BMI was 29.38 (7.74) kg/m².

The median levels of LDH and D-dimer on admission were 974.5 (517.75 to 1595) and 827.5 (567.5 to 1612.5), respectively.

Eight out of nine patients had abdominal pain and tenderness before hematoma, and eight had a cough as a minor trauma. One patient with a past medical history of myasthenia gravis had a right femoral catheter and received plasmapheresis four times before RSH. Since RSH in this patient could be due to the femoral catheter, considering the catheter as a confounding factor for RSH, her outcome was not included in the analysis.

It should be mentioned that all of the patients received antithrombotic drugs and steroids besides anticoagulation. All of them were on a daily dose of dexamethasone (8 mg) and acetylsalicylic acid (80 mg), and three of them with a past medical history of ischemic heart disease (IHD) received clopidogrel 75 mg. They continued to take their prescribed medications until a diagnosis of RSH was made.

All of the nine patients received subcutaneous injections of anticoagulant treatment at prophylactic or therapeutic doses as a routine ward practice. Six patients (66.6%) received therapeutic and others received prophylactic anticoagulation. Regarding the severity of COVID-19 at baseline, three (33.3%) hemodynamically unstable patients were already admitted to the intensive care unit (ICU) when RSH developed. Three others gradually became worse following bleeding and were transferred to the ICU. Another patient who was firstly admitted to the ward eventually died following an abrupt decrease in hemoglobin before ICU transfer. Table 2 presents the details of all patients during hospitalization and their outcome.

Coagulation problems in most patients were corrected (achieving blood hemoglobin over 9 g/dL) with packed red blood cells (PRBCs). Three cases needed to receive fresh frozen plasma (FFP) as they had ongoing bleeding. More than half of the patients (66.7%) were admitted to the ICU. A 65-year-old female with moderate to severe confirmed COVID-19 developed a massive blushing hematoma following anticoagulant therapy, which was suspicious for extravasation on sonography. After receiving anticoagulation reversal procedures and fluid resuscitation, she was admitted to the catheterization laboratory (cath lab) for selective angioembolization in a tachycardia state before hypovolemic shock occurred. Selective angiography of the internal iliac and external iliac artery branches revealed no extravasation, and she did not require any special interventions on angiography.

Although appropriate surgical approaches were adopted including fluid resuscitation and correction of coagulopathy, five out of nine cases died. Hematoma resolved with conservative management in the youngest patients with moderate to severe COVID-19.

4. Discussion

Although RSH is an uncommon and self-limited cause of abdominal pain, it has become a new life-threatening
concern among patients with COVID-19. While the mortality rate of RSH patients receiving anticoagulant treatment has been estimated at 4–25% in other patients [16], more than half of the cases in this study died despite receiving appropriate care in well-equipped referral hospitals (mortality rate was 55.5%). This rare occurrence is particularly associated with anticoagulant therapy [2, 17].

Considering the high prevalence of hypercoagulopathy state and the high risk of venous thromboembolism (VTE), anticoagulant therapy plays an important role, especially among hospitalized patients that are immobile due to severe pulmonary involvement. Reduced mobility, respiratory failure, obesity, and advanced age (>70) are predisposing factors for VTE as demonstrated in previous studies [18]. Besides, the prevalence of VTE has been reported to be higher in bedridden patients due to COVID-19 pneumonia, which can be predicted using D-dimer levels, especially in severe COVID-19 pneumonia [19]. In addition, studies have shown a higher incidence of pulmonary thromboembolism (PTE) in COVID-19 patients [20].

The role of laboratory markers such as D-dimer and LDH predicting the severe course of COVID-19 has been proven in recent studies [21], especially in thrombotic events [22]. For instance, an increased level of D-dimer can be a prognostic factor for bleeding or thrombotic complications, critical illness, and death. The elevated LDH is identified as a risk factor for thrombosis in patients with COVID-19 as well [22, 23]. Besides, LDH has long been an early inflammatory marker of hemolysis to predict thrombosis in patients with ventricular assist devices in articles [24, 25].

Since the COVID-19 can intervene in intravascular systems, the majority of all deaths in patients with COVID-19 are attributed to VTE and disseminated intravascular coagulation (DIC) which are consequences of the systemic inflammatory response [26, 27]. PTE is also associated with marked changes in some laboratory markers such as D-dimer and LDH according to recent radiologic surveys [28, 29], that is why proper anticoagulant treatment to reduce PTE complications in COVID-19 patients is so crucial.

The optimal dose of thromboprophylaxis has yet to be determined; therefore, in this study, any decrease in blood oxygen despite routine treatment made the clinicians switch from a prophylactic dose to a therapeutic dose. Although none of the patients in this study had confirmed VTE/PE on CT imaging, clinicians are interested in anticoagulant therapy considering recent studies endorsing a reduction in the use of respiratory or cardiovascular organ support following the administration of therapeutic doses of anticoagulants [30]. Besides, the rising trend of D-dimer and LDH at the same time was also suggestive of VTE or PTE in these acutely ill patients.

Although thromboprophylaxis, if not contraindicated, has been proved to be beneficial in hospitalized patients with COVID-19 [31, 32], there are reports of RSH [33] in these patients [8, 9].

Considering a recent Canadian report indicating a chance of about 5.6% for major bleeding in these patients [34], five patients in this study received therapeutic anticoagulation treatment according to the American College of Chest Physicians guidelines [35], and the others received prophylactic doses instead as a routine ward practice until a diagnosis of rectus sheath hematoma was confirmed [36]. Even though some studies have warned against LMWH (enoxaparin) [33], most of the cases received this drug due to its availability and reasonable price. Comorbidities such as hypertension (HTN) and diabetes mellitus (DM) as well as high D-dimer levels on admission have been considered as factors associated with a poor prognosis in COVID-19 patients [37] (Table 2).

Despite all efforts to overcome blood loss, restore stable vital signs, and stabilize RSH without any reduction in blood hemoglobin (over 9), the mortality rate was more than expected among these COVID-19 patients (55.5%). It seems that due to the deterioration of the underlying viral disease, their condition became worse unexpectedly.

According to similar studies, most of the cases in this study had multiple risk factors for RSH, which increased the risk of RSH during hospitalization [38]. All cases, except one, were female, and female gender is a major predisposing factor for RSH. Except for one with femoral catheterization, half of the other COVID-19 patients (50%) were admitted with a gastrointestinal presentation (nausea, vomiting, diarrhea, abdominal pain, etc.). All patients received subcutaneous injections of anticoagulants in the abdomen, and most of them (87.5%) had at least either abdominal pain or cough right before RSH. By paying timely attention to these

**Table 1: COVID-19 severity and vital sign summary in admission time.**

| Patient number | COVID-19 severity   | O₂ SAT (%) | SBP    | DBP    | Max Hb | Min Hb |
|----------------|---------------------|------------|--------|--------|--------|--------|
| 1              | Severe              | 87         | 140    | 75     | 11.8   | 8.9    |
| 2              | Severe              | 75         | 140    | 85     | 10.5   | 8.6    |
| 3              | Severe              | 75         | 116    | 65     | 11     | 8      |
| 4              | Moderate to severe  | 67         | 110    | 70     | 12     | 7      |
| 5              | Moderate to severe  | 94         | 140    | 80     | 14.4   | 6.8    |
| 6              | Moderate to severe  | 85         | 120    | 80     | 13     | 9      |
| 7              | Moderate to severe  | 89         | 170    | 85     | 12.9   | 5.7    |
| 8              | Moderate            | 70         | 110    | 70     | 13.5   | 7.5    |
| 9              | Mild to moderate    | 86         | 110    | 70     | 11     | 8.5    |

SBP: systolic blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); Hb: hemoglobin; O₂ SAT (%): oxygen saturation (without oxygen support); Max: maximum; Min: minimum (bleeding time).
| Patient | BMI (kg/m²) | Past medical history | Laboratory findings | Anticoagulant Regimen | Total received days | Total received dosage | Complication | Location of RSH | Size of RSH | Management | Admitted to | Total hospitalization stay | Outcome  |
|---------|-------------|----------------------|---------------------|------------------------|---------------------|---------------------|--------------|----------------|-------------|------------|-------------|------------------------|-----------|
| A 78-year-old female | 27.34 | HTN | 99 1410 2300 | LMWH (therapeutic dose) | 14 | 60 daily | Unilateral massive RSH | Unclear | PRBC | ICU | 20 | Expired |
| A 61-year-old female | 33.30 | None | 124 NA 1600 | LMWH (therapeutic dose) | 15 | 60 BD | Bilateral expanded to hypogastric zone and free fluid in the pelvic | 64*89 mm 59*29 mm 76*22 mm | PRBC | ICU | 37 | Expired |
| A 78-year-old female | 37.00 | IHD, HTN, and arrhythmia | 120 685 482 | UFH (prophylactic dose) | 5 | 5000 TDS | Unilateral massive RSH | Infra oblique hematoma, expansion to pelvic with probable extravasation, and free fluid in the abdomen | Maximum size of 170*155*90 mm (150 cc) | PRBC, FFP, fibrinogen, and factor VII infusion | Ward, then ICU and cath lab | 13 | Expired |
| A 65-year-old female | 28.30 | DM | 71 2735 1183 | LMWH (therapeutic dose) | 10 | 60 BD | Infra oblique hematoma, expansion to pelvic with probable extravasation, and free fluid in the abdomen | Maximum size of 130*65 mm | PRBC | Ward | 7 | Expired |
| An 83-year-old female | 20.60 | IHD and asthma | 12 1680 1580 | LMWH (therapeutic dose) | 7 | 60 BD | Massive bilateral RSH | maximum size of 130*65 mm | PRBC | Ward | 7 | Expired |
| A 43-year-old female | 29.74 | DM | 85 650 625 | LMWH (therapeutic dose) | 9 | 60 BD | Left unilateral RSH | 326*92*42 mm | Conservative | Ward, then ICU | 26 | Discharged |
| A 67-year-old female | 25.39 | HTN and IHD | 142 540 465 | LMWH (therapeutic dose) | 14 | 60 BD | Retroperitoneal and hypogastric RSH with expansion to pelvic | 110*108*128 mm in size (790 cc) | PRBC and FFP infusion | Ward, then ICU | 20 | Discharged |
| A 50-year-old female | 29.38 | HTN, DM, and MG | 110 970 766 | LMWH (therapeutic dose) | 10 | 60 BD | Bilateral RSH with expansion to latissimus dorsi | Maximum size of 134*67 (330 cc) | PRBC and FFP infusion | Ward | 21 | Discharged |

Table 2: Study case summary.
### Table 2: Continued.

| Patient | BMI (kg/m²) | Past medical history | Laboratory findings | Anticoagulant Regimen | Total received days | Total received dosage | Complication | Location of RSH | Size of RSH | Management | Admitted to | Total hospitalization stay | Final status |
|---------|-------------|----------------------|---------------------|------------------------|---------------------|----------------------|--------------|----------------|------------|------------|------------|---------------------------|--------------|
| A 62-year-old male | 19.60 | DM and KT | CRP | UFH (prophylactic dose) | 5 | 5000 TDS | Retro rectus hematoma in latissimus dorsi and free fluid in the abdomen | Not lobulated, volume/size was not detectable | PRBC | Ward | 17 | Discharged |

BMI: body mass index; HTN: hypertension; DM: diabetes mellitus; IHD: ischemic heart disease; MG: myasthenia gravis; KT: kidney transplant; CRP: C-reactive protein; LDH: lactic acid dehydrogenase; ICU: intensive care unit; UFH: unfractionated heparin; LMWH: low-molecular weight heparin (enoxaparin); BD: twice a day; TDS: three times a day; PRBC: packed red blood cell.
clues, clinicians can manage this fatal complication more properly.

5. Limitation

Since central venous catheterization is associated with a risk of bleeding in medical patients [39], the patient with myasthenia gravis who developed RSH after receiving plasmapheresis through the femoral catheter was not included in the analysis.

Two ultrasound reports containing information on the size and location of RSH were not available; therefore, they were only described qualitatively.

6. Conclusion

Although RSH is usually self-limited and has a good prognosis, it can be a life-threatening complication in COVID-19 patients receiving anticoagulant treatment. Hospitalized COVID-19 patients with RSH risk factors should be identified on admission, and healthcare providers should bear in mind the utmost significance of an abrupt decrease in the hemoglobin level together with an increase in inflammatory markers such as LDH in these patients during daily visits. Further studies in larger sample sizes are needed to find better management options for COVID-19 patients with RSH.

Data Availability

The data used to support the findings of this study are available on request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] N. P. Tsapatsaris, "Low-dose heparin. A cause of hematoma of rectus abdominis," *Archives of Internal Medicine*, vol. 151, no. 3, pp. 597–599, 1991.

[2] P. J. Klingler, G. Wetscher, K. Glaser, J. Tschmelitsch, T. Schmid, and R. A. Hinder, "The use of ultrasound to differentiate rectus sheath hematoma from other acute abdominal disorders," *Surgical Endoscopy*, vol. 13, no. 11, pp. 1129–1134, 1999.

[3] J. A. Edlow, P. Juang, S. Margulies, and J. Burststein, "Rectus sheath hematoma," *Annals of Emergency Medicine*, vol. 34, no. 5, pp. 671–675, 1999.

[4] K. B. Webb and S. Hadzima, "Hematoma of the rectus abdominis muscle: a complication of subcutaneous heparin therapy," *Southern Medical Journal*, vol. 80, no. 7, pp. 911–912, 1987.

[5] R. James, "Rectus sheath hematoma," *The Lancet*, vol. 365, no. 9473, p. 1824, 2005.

[6] A. M. Gallego, J. L. Aguayo, B. Flores et al., "Ultrasonography and computed tomography reduce unnecessary surgery in abdominal rectus sheath hematoma," *British Journal of Surgery*, vol. 84, no. 9, pp. 1295–1297, 1997.

[7] T. Fukuda, I. Sakamoto, S. Kohzaki et al., "Spontaneous rectus sheath hematomas: clinical and radiological features," *Abdominal Imaging*, vol. 21, no. 1, pp. 58–61, 1996.

[8] J. J. Dennison, S. Carlson, S. Faehling, H. Phelan, M. Tariq, and A. Mubarak, "Splenic infarction and spontaneous rectus sheath hematomas in COVID-19 patient," *Radiology Case Reports*, vol. 16, no. 5, pp. 999–1004, 2021.

[9] B. Nematihonar, S. Qaderi, J. Shah, and J. Z. Bagherpour, "Spontaneous giant rectus sheath hematoma in patients with COVID-19: two case reports and literature review," *International Journal of Emergency Medicine*, vol. 14, no. 1, pp. 40–46, 2021.

[10] T. Kalayci, "Rectus sheath hematoma due to Low molecular weight heparin in a COVID-19 patient in Turkey," *Cureus*, vol. 13, no. 5, Article ID e14870, 2021.

[11] I. Bakirov, G. Bakirova, and Y. Albalawi, "Left inferior epigastric artery injury in COVID-19 patient. Case report and literature review," *International Journal of Surgery Case Reports*, vol. 76, 2020.

[12] A. Hajian, "A case series of life-threatening hemorrhagic events in patients with COVID-19," *Indian Journal of Surgery*, vol. 8, pp. 1–7, 2021.

[13] P. Hazenberg, S. Lechareas, M. Vasquez Rios, M. Taegtmeyer, R. McWilliams, and T. Dutt, "Rectus sheath and retroperitoneal hematomas in patients with Coronavirus 2019 infection," *British Journal of Haematology*, vol. 194, 2021.

[14] G. D. Barnes, A. Burnett, A. Allen et al., "Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum," *Journal of Thrombosis and Thrombolysis*, vol. 50, no. 1, pp. 72–81, 2020.

[15] B. N. Contrella, A. W. Park, L. R. Wilkins, D. Sheenan, T. E. Hassinger, and J. F. Angle, "Spontaneous rectus sheath hematoma: factors predictive of conservative management failure," *Journal of Vascular and Interventional Radiology*, vol. 31, no. 2, pp. 323–330, 2020.

[16] O. Osinbowale and J. R. Bartholomew, "Rectus sheath hematoma," *Vascular Medicine*, vol. 13, no. 4, pp. 275–279, 2008.

[17] W. B. Cherry and P. S. Mueller, "Rectus sheath hematoma," *Medicine*, vol. 85, no. 2, pp. 105–110, 2006.

[18] S. Barbar, F. Noventa, V. Rossetto et al., "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score," *Journal of Thrombosis and Haemostasis*, vol. 8, no. 11, pp. 2450–2457, 2010.

[19] S. Cui, S. Chen, X. Li, S. Liu, and F. Wang, "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia," *Journal of Thrombosis and Haemostasis*, vol. 18, no. 6, pp. 1421–1424, 2020.

[20] F. Grillet, J. Behr, P. Calame, S. Aubry, and E. Delabrousse, "Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography," *Radiology*, vol. 296, no. 3, pp. E186–E188, 2020.

[21] S. Katzenschlager, A. J. Zimmer, C. Gottschalk et al., "Can we predict the severe course of COVID-19 - a systematic review and meta-analysis of indicators of clinical outcome?" *PLoS One*, vol. 16, no. 7, Article ID e0255154, 2021.

[22] X. Xiong, J. Ji, and Q. Gao, "Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis," *Thrombosis Journal*, vol. 19, no. 1, p. 32, 2021.

[23] H. Al-Samkari, R. S. Karp Leaf, W. H. Dzik et al., "COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection," *Blood*, vol. 136, no. 4, pp. 489–500, 2020.

[24] J. A. Cowger, M. A. Romano, P. Shah et al., "Hemolysis: a harbinger of adverse outcome after left ventricular assist
device implant,” The Journal of Heart and Lung Transplantation, vol. 33, no. 1, pp. 35–43, 2014.
[25] J. S. Gordon, C. T. Wood, J. G. Y. Luc et al., “Clinical implications of LDH isoenzymes in hemolysis and continuous-flow left ventricular assist device-induced thrombosis,” Artificial Organs, vol. 44, no. 3, pp. 231–238, 2020.
[26] N. Tang, H. Bai, X. Chen, J. Gong, D. Li, and Z. Sun, “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy,” Journal of Thrombosis and Haemostasis, vol. 18, no. 5, pp. 1094–1099, 2020.
[27] A. Almeida, V. V. Azcárate, and C. S. Justicia, “Severe colon ischemia in patients with severe covid-19 infection: a report of three cases,” Revista espanola de enfermedades digestivas, vol. 112, 2020.
[28] E. Cavagna, F. Muratore, and F. Ferrari, “Pulmonary thromboembolism in COVID-19: venous thromboembolism or arterial thrombosis?” Radiology: Cardiothoracic Imaging, vol. 2, no. 4, Article ID e200289, 2020.
[29] S.-q. Ben, S.-s. Ni, H.-h. Shen et al., “The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine,” Thrombosis Research, vol. 120, no. 4, pp. 575–583, 2007.
[30] A. Investigators, A.-a Investigators, and R.-C. Investigators, “Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19,” New England Journal of Medicine, vol. 385, 2021.
[31] J. Thachil, N. Tang, S. Gando et al., “ISTH interim guidance on recognition and management of coagulopathy in COVID-19,” Journal of Thrombosis and Haemostasis, vol. 18, no. 5, pp. 1023–1026, 2020.
[32] I. Romic, G. Pavlek, M. Mance, M. Romic, and T. Moric, “Fatal case of spontaneous rectus sheath hematoma caused by anticoagulant and steroid therapy during hospital admission,” Visceral medicine, vol. 34, no. 3, pp. 225–227, 2018.
[33] D. Mendes, A. Penedones, M. Martins, S. Cavadas, C. Alves, and F. Batel-Marques, “Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: a case series of five patients,” Clinical Case Reports, vol. 8, no. 12, pp. 3432–3439, 2020.
[34] N. C. Chan and J. I. Weitz, “COVID-19 coagulopathy, thrombosis, and bleeding,” Blood, vol. 136, no. 4, pp. 381–383, 2020.
[35] S. R. Kahn, W. Lim, and A. S. Dunn, “Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e195S–e226S, 2012.
[36] C. Kearon, E. A. Akl, and A. J. Comerota, “Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e419S–e96S, 2012.
[37] F. Zhou, T. Yu, R. Du et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” The Lancet, vol. 395, no. 10229, pp. 1054–1062, 2020.
[38] A. Hatijepetrou, D. Anyfantakis, and M. Kastanakis, “Rectus sheath hematoma: a review of the literature,” International Journal of Surgery, vol. 13, pp. 267–271, 2015.
[39] H. Decousus, V. F. Tapson, J.-F. Bergmann et al., “Factors at admission associated with bleeding risk in medical patients,” Chest, vol. 139, no. 1, pp. 69–79, 2011.